Stay updated on Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page.

Latest updates to the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page
- Check4 days agoChange DetectedUpdated the site revision tag to v3.4.3 and removed the previous v3.4.2 reference.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision history updated: added v3.4.2 and removed v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this internal version change does not alter user-facing content or functionality.SummaryDifference0.1%

- Check47 days agoChange DetectedNew: Show glossary toggle, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 with no substantive changes to study content, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedA top-level Locations section was added listing California, Massachusetts, New York, North Carolina, Texas, and Utah. The previous per-state location subsections (California Locations, Massachusetts Locations, New York Locations, North Carolina Locations, Texas Locations, Utah Locations) were removed.SummaryDifference0.7%

Stay in the know with updates to Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page.